0.00Open0.05Pre Close0 Volume10 Open Interest0.50Strike Price0.00Turnover0.00%IV-77.83%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type--Delta--Gamma40.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
BioXcel Therapeutics Stock Discussion
NEWS
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
The late-breaking abstract on preliminary findings from the Phase 2 trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeti...
13 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
No comment yet